Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Nick Andrews et al.
Summary: A study conducted in England showed that vaccines against SARS-CoV-2 provide high protection against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. However, the effectiveness of the vaccines decreases over time, especially in individuals aged 65 and older and those with underlying risk factors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Infectious Diseases
Sharif A. Ismail et al.
Summary: This study estimated the rate of SARS-CoV-2 infection and outbreaks among staff and students in educational settings in England during the summer half-term of 2020, finding that infections and outbreaks were uncommon in educational settings, but strongly associated with regional COVID-19 incidence. The results emphasize the importance of controlling community transmission to protect educational settings, with interventions focusing on reducing transmission among staff.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Laith J. Abu-Raddad et al.
Summary: This study aimed to assess the protection against breakthrough infection with SARS-CoV-2 after mRNA vaccination, comparing individuals with and without prior infection. The findings showed that individuals with prior SARS-CoV-2 infection had a significantly lower risk for breakthrough infection, indicating a potential benefit of natural immunity in vaccine protection.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Medicine, General & Internal
Noam Barda et al.
Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.
Article
Biochemistry & Molecular Biology
Koen B. Pouwels et al.
Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Ronen Arbel et al.
Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Barak Mizrahi et al.
Summary: The study indicates preliminary evidence of waning vaccine effectiveness of BNT162b2 among all age groups above 16, with a higher incidence of infection in those vaccinated earlier in 2021. Further investigation into long-term protection against different strains is warranted.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Gayatri Amirthalingam et al.
Summary: The UK extended the interval between COVID-19 vaccine doses to 12 weeks, leading to higher antibody levels and estimated greater vaccine effectiveness. This study highlights the importance of an extended vaccine schedule in enhancing protection against COVID-19.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Ariel Israel et al.
Summary: In this study, it was found that the risk of COVID-19 infection gradually increased in adults who received their second dose of the BNT162b2 mRNA vaccine after at least 90 days, based on electronic health records.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Medicine, General & Internal
Eleftheria Vasileiou et al.
Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.
Article
Medicine, General & Internal
Jamie Lopez Bernal et al.
Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Infectious Diseases
Catherine Hyams et al.
Summary: The study found that one dose of either the BNT162b2 or ChAdOx1 nCoV-19 vaccines resulted in substantial risk reductions for COVID-19-related hospitalisations in those aged over 80 years.
LANCET INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Emma Pritchard et al.
Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)